中欧抗体权利要求的规定比较浅析

Comparative Analysis of Chinese and European Provisions on Antibody Claims

本文针对抗体权利要求,比较了新版《欧洲专利局审查指南》与我国现行《专利审查指南》中的规定,并结合实际专利审查和代理实务操作进行对比分析,并介绍创造性判断的实例。总体来说,欧洲专利局的审查指南关于抗体方面的规定更加详细一些,比较可知,除杂交瘤限定的抗体外,对于使用结构限定、靶标抗原限定、靶标抗原及抗体功能特性限定、表位限定、功能和结构特点限定、以及制备方法限定的抗体,欧洲专利局新审查指南的规定与我国现行专利审查指南的规定及专利实务操作存在一些不同。

This paper is about antibody patent application,and comparation of the new version of the Guidelines for Examination in the European Patent Office with the current version of the Guidelines for Patent Examination in China.The comparative analyses including the actual patent examination,agency practice and introduction of some examples of creative judgment are made.Generally speaking,the regulations on antibodies of the European Patent Office are more detailed in advance.It can be seen from the comparison that the provisions about antibodies limited by hybridoma in the new guidelines of the European Patent Office are the same as those in China.For antibodies limited by structure,target antigen,functional characteristics of target antigen and antibody,epitope,functional and structural characteristics,and preparation methods,there are some differences in Chinese current guidelines and patent practice.